Latest Insider Transactions at Recursion Pharmaceuticals, Inc. (RXRX)
This section provides a real-time view of insider transactions for Recursion Pharmaceuticals, Inc. (RXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RECURSION PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RECURSION PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2026
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
220,000
-3.2%
|
$880,000
$4.36 P/Share
|
|
Jan 05
2026
|
Christopher Gibson Director |
SELL
Bona fide gift
|
Direct |
20,000
-2.14%
|
-
|
|
Jan 05
2026
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
40,000
-4.11%
|
$160,000
$4.25 P/Share
|
|
Jan 05
2026
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
60,000
+5.8%
|
-
|
|
Jan 02
2026
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,381
+0.19%
|
-
|
|
Jan 02
2026
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,571
+2.45%
|
-
|
|
Dec 29
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
21,383
-2.73%
|
$85,532
$4.18 P/Share
|
|
Dec 22
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Open market or private sale
|
Direct |
124,403
-16.91%
|
$497,612
$4.41 P/Share
|
|
Dec 19
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
40,000
-4.19%
|
$160,000
$4.5 P/Share
|
|
Dec 19
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
40,000
+4.02%
|
-
|
|
Dec 15
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,057
-0.89%
|
$28,228
$4.33 P/Share
|
|
Dec 04
2025
|
Christopher Gibson Director |
SELL
Bona fide gift
|
Direct |
20,000
-2.14%
|
-
|
|
Dec 04
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
40,000
-4.11%
|
$160,000
$4.63 P/Share
|
|
Dec 04
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
60,000
+5.8%
|
-
|
|
Dec 02
2025
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
220,000
-3.1%
|
$880,000
$4.37 P/Share
|
|
Nov 25
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,271
-0.29%
|
$9,084
$4.03 P/Share
|
|
Nov 19
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
40,000
-4.19%
|
$160,000
$4.16 P/Share
|
|
Nov 19
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
40,000
+4.02%
|
-
|
|
Nov 17
2025
|
Christopher Gibson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
40,390
-4.23%
|
$161,560
$4.14 P/Share
|
|
Nov 17
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,584
-2.33%
|
$70,336
$4.14 P/Share
|
|
Nov 17
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,908
-1.48%
|
$47,632
$4.14 P/Share
|
|
Nov 05
2025
|
Najat Khan Chief R&D Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
84,925
+10.13%
|
-
|
|
Nov 04
2025
|
Christopher Gibson Director |
SELL
Bona fide gift
|
Direct |
20,000
-2.05%
|
-
|
|
Nov 04
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
40,000
-3.94%
|
$200,000
$5.21 P/Share
|
|
Nov 04
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
60,000
+5.59%
|
-
|
|
Oct 23
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$500,000
$5.7 P/Share
|
|
Oct 23
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Oct 10
2025
|
Christopher Gibson Director |
SELL
Bona fide gift
|
Direct |
20,000
-2.05%
|
-
|
|
Oct 10
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
100,000
-9.31%
|
$600,000
$6.04 P/Share
|
|
Oct 10
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
120,000
+10.05%
|
-
|
|
Oct 01
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,941
+2.08%
|
-
|
|
Oct 01
2025
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,961
+0.16%
|
-
|
|
Sep 25
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$400,000
$4.76 P/Share
|
|
Sep 25
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Sep 15
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,057
-0.87%
|
$28,228
$4.83 P/Share
|
|
Sep 10
2025
|
Christopher Gibson Director |
SELL
Bona fide gift
|
Direct |
20,000
-2.05%
|
-
|
|
Sep 10
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
100,000
-9.31%
|
$400,000
$4.71 P/Share
|
|
Sep 10
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
120,000
+10.05%
|
-
|
|
Aug 26
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$400,000
$4.84 P/Share
|
|
Aug 26
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Aug 18
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Open market or private sale
|
Direct |
36,599
-5.19%
|
$182,995
$5.52 P/Share
|
|
Aug 15
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,789
-0.53%
|
$18,945
$5.64 P/Share
|
|
Aug 15
2025
|
Christopher Gibson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
40,390
-4.06%
|
$201,950
$5.64 P/Share
|
|
Aug 15
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,908
-1.45%
|
$59,540
$5.64 P/Share
|
|
Aug 11
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Indirect |
117,875
-100.0%
|
$589,375
$5.28 P/Share
|
|
Aug 11
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Indirect |
117,875
+50.0%
|
-
|
|
Aug 11
2025
|
Christopher Gibson Director |
SELL
Bona fide gift
|
Direct |
10,000
-1.0%
|
-
|
|
Aug 11
2025
|
Christopher Gibson Director |
SELL
Open market or private sale
|
Direct |
500,300
-33.24%
|
$2,501,500
$5.28 P/Share
|
|
Aug 11
2025
|
Christopher Gibson Director |
BUY
Conversion of derivative security
|
Direct |
423,666
+21.97%
|
-
|
|
Jul 01
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,924
+2.11%
|
-
|